OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone240-813-1260
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.95 million
Profitability
Miscellaneous
Employees44
Next Earnings Date8/1/2019 (Estimated)
OptionableNot Optionable
OpGen (NASDAQ:OPGN) Frequently Asked Questions
What is OpGen's stock symbol?
OpGen trades on the NASDAQ under the ticker symbol "OPGN."
When did OpGen's stock split? How did OpGen's stock split work?
OpGen's stock reverse split on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.
How were OpGen's earnings last quarter?
OpGen Inc (NASDAQ:OPGN) issued its quarterly earnings results on Tuesday, May, 14th. The medical research company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.08. The medical research company had revenue of $1.02 million for the quarter, compared to analyst estimates of $1.20 million. OpGen had a negative return on equity of 313.92% and a negative net margin of 454.23%. View OpGen's Earnings History.
When is OpGen's next earnings date?
What price target have analysts set for OPGN?
2 Wall Street analysts have issued twelve-month price objectives for OpGen's stock. Their predictions range from $1.50 to $2.30. On average, they anticipate OpGen's share price to reach $1.90 in the next twelve months. This suggests a possible upside of 475.8% from the stock's current price. View Analyst Price Targets for OpGen.
What is the consensus analysts' recommendation for OpGen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.
What are Wall Street analysts saying about OpGen stock?
Here are some recent quotes from research analysts about OpGen stock:
- 1. According to Zacks Investment Research, "OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. " (6/18/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $71M. This includes a discounted cash flow analysis based enterprise value of $72M for the QuickFISH and Acuitas products, with a 15% discount rate and 2% terminal growth rate, excluding $1M debt." (5/19/2019)
Has OpGen been receiving favorable news coverage?
News articles about OPGN stock have been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OpGen earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for OpGen.
Are investors shorting OpGen?
OpGen saw a increase in short interest in June. As of June 30th, there was short interest totalling 128,600 shares, an increase of 37.2% from the May 30th total of 93,700 shares. Based on an average daily volume of 483,600 shares, the days-to-cover ratio is presently 0.3 days. Currently, 1.6% of the shares of the stock are short sold. View OpGen's Current Options Chain.
Who are some of OpGen's key competitors?
What other stocks do shareholders of OpGen own?
Who are OpGen's key executives?
OpGen's management team includes the folowing people:
- Mr. Evan Jones, Chairman & CEO (Age 62)
- Mr. Timothy C. Dec, CFO & Corp. Sec. (Age 60)
- Mr. Vadim Sapiro, Chief Information Officer (Age 48)
- Mr. Michael Farmer, VP of Marketing
- Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60)
When did OpGen IPO?
(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.
How do I buy shares of OpGen?
Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OpGen's stock price today?
One share of OPGN stock can currently be purchased for approximately $0.33.
How big of a company is OpGen?
OpGen has a market capitalization of $5.82 million and generates $2.95 million in revenue each year. The medical research company earns $-13,370,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. OpGen employs 44 workers across the globe.View Additional Information About OpGen.
What is OpGen's official website?
How can I contact OpGen?
OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]
MarketBeat Community Rating for OpGen (NASDAQ OPGN)
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
